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Novel N4-hydroxy- and 5-methyl-modified -L-deoxycytidine analogues were synthesized and evaluated as
anti-hepatitis B virus (HBV) agents. Their in vitro efficiencies were investigated in HepG2.2.15 cells stably
transfected with HBV. -L-2,3-Didehydro-2,3-dideoxy-N4-hydroxycytidine (-L-Hyd4C) was most effective in
reducing secreted HBV DNA (50% effective concentration [EC50], 0.03 M), followed by -L-2,3-dideoxy-3-
thia-N4-hydroxycytidine (EC50, 0.51 M), -L-2,3-dideoxy-N
4-hydroxycytidine (EC50, 0.55 M), and -L-5-
methyl-2-deoxycytidine (EC50, 0.9 M). The inhibition of the presumed target, the HBV DNA polymerase, by
the triphosphates of some of the -L-cytidine derivatives was also assessed. In accordance with the cell culture
data, -L-Hyd4C triphosphate was the most active inhibitor, with a 50% inhibitory concentration of 0.21 M.
The cytotoxicities of some of the 4-NHOH-modified -L-nucleosides were dramatically lower than those of the
corresponding cytidine analogues with the unmodified 4-NH2 group. The 50% cytotoxic concentrations for
-L-Hyd4C in HepG2 and HL-60 cells were 2,500 M and 3,500 M, respectively. In summary, our results
demonstrate that at least -L-Hyd4C can be recommended as a highly efficient and extremely selective inhibitor
of HBV replication for further investigations.
Complete and sustained suppression of viral replication re-
mains the most important goal in the treatment of patients with
chronic hepatitis B virus (HBV) infection. Nucleoside and nucle-
otide analogues have greatly improved the disease outcome for
these patients and have also prevented hepatic decompensation
or the development of hepatocellular carcinoma. While -L-2,3-
dideoxy-3-thiacytidine (3TC; lamivudine) has been approved for
the treatment of HBV infections, a series of further -L-
nucleosides are under clinical investigation as inhibitors of
hepadnavirus infections. These include -L-2,3-dideoxy-3-
thia-5-fluorocytidine (FTC), -L-2,3-didehydro-2,3-dideoxy-5-
fluorocytidine (-L-Fd4C), -L-2-fluoro-5-methyl-arabinosylura-
cil (-L-FMAU), and -L-thymidine (-L-dT) (40).
The most important advantage associated with some, but not
all, of these -L-nucleosides seems to be a much higher selec-
tivity for the viral target than for the cellular targets, resulting
in reduced cytotoxicity. This quality of -L-nucleosides stimu-
lated the search for new -L-nucleosides but also the synthesis
of enantiomeric isomers of effective -D-nucleosides (7).
Some of the unmodified pyrimidine and purine -L-nucleo-
sides were synthesized for the first time more than 35 years ago
(12, 28, 34) but were considered to be metabolized very poorly
in mice (14). A systematic biochemical investigation of the
-L-enantiomers was initiated later and demonstrated the anti-
human immunodeficiency virus (HIV) activity of -L-2,3-
dideoxycytidine (-L-ddC) in a cellular system (18). In addi-
tion, it was shown that -L-dT might be phosphorylated by
herpes simplex virus type 1 (HSV-1) thymidine kinase and
further, by cellular enzymes, to -L-dTTP (35).
As a consequence, the effects of -L-dTTP on various cellu-
lar DNA polymerases, TdT, the Klenow fragment of Esche-
richia coli DNA polymerase I, and viral DNA polymerases such
as HSV-1 DNA polymerase and HIV reverse transcriptase
were investigated (6, 32, 38). We showed that -L-TTP does
not influence the activity of any of the cellular DNA poly-
merases (, , , , or ε) or of HIV reverse transcriptase, but
we demonstrated for the first time a strong inhibition of human
and duck HBV DNA polymerases by -L-dTTP (concentra-
tions resulting in 50% inhibition of HBV DNA polymerase
activity [IC50], 0.46 M and 1.0 M, respectively) (37). Inves-
tigations on the cellular level and in vivo experiments have
confirmed that -L-dT is a promising and highly selective in-
hibitor of HBV replication (3). This is also true for -L-deoxy-
cytidine (-L-CdR) and -L-deoxyadenosine (-L-AdR) (3).
On the basis of these findings, we synthesized a series of
-L-N4-hydroxydeoxycytidine analogues and various -L-5-
methyl-deoxycytidine derivatives, evaluated their potential as
inhibitors of HBV replication in cell culture, and tested the
triphosphates of some of the -L-nucleosides directly on HBV
DNA polymerase.
Among the newly synthesized compounds, -L-2,3-didehy-
dro-2,3-dideoxy-N4-hydroxycytidine (-L-Hyd4C) emerged as
a strong and highly selective inhibitor of HBV replication.
MATERIALS AND METHODS
Compounds. The N4-hydroxy- and 5-methyl-modified -L-deoxycytidine ana-
logues were synthesized by methods described previously (E. Matthes, M. von
Janta-Lipinski, H. Will, H. Sirma, and A. Funk, 21 October 2005, European patent
application PCT/EP2005/011555; E. Matthes, M. von Janta-Lipinski, H. Will, H.
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Sirma, and L. Lin, 13 September 2004, worldwide patent application WO2005/
026186 A1). 1H and 13C nuclear magnetic resonance (NMR) spectra were re-
corded on a Bruker DRX 600 instrument with tetramethylsilane as an internal
standard. ASCA GmbH, Berlin, Germany, performed combustion analyses.
High-performance liquid chromatography (HPLC) analyses were performed on a
Shimadzu 10AVP system using a reverse-phase analytical column (Zorbax, 300SB-
C18; inner diameter, 5 m; 4.5 by 250 mm), eluting with a linear gradient of 100%
A (water) to 100% B (acetonitrile) over 15 min at a flow rate of 1 ml/min.
Data are given for the most effective compounds of each modification:
-L-Hyd4C, representative of the -L-N4-hydroxydeoxycytidine analogues,
and -L-5-methyl-2-deoxycytidine (-L-MetCdR), representative of the -L-
5-methyl-deoxycytidine derivatives.
1-(2,3-Dideoxy--L-glycero-pent-2-enofuranosyl)-4-hydroxyamino-pyrimidin-
2(1H)-one (-L-Hyd4C) was obtained as a white amorphous material. 1H NMR
(dimethyl sulfoxide [DMSO]-d6)  10.96, 10.01 (2H, 2s, NH4, OH-4), 7.64 (1H,
s, H-6), 6.58 (1H, d, H-1), 6.37 (1H, dd, H-3), 6.23 (1H, dd, H-2), 5.53 (1H, d,
H-5), 5.21 (1H, t, OH-5), 4.20 to 4.12 (1H, m, H-4), 3.75 to 3.52 (2H, m, H-5,
H-5). 13C NMR (DMSO-d6)  35.22 (C-2), 67.13 (C-5), 69.27(C-3), 82.64
(C-1), 86.47 (C-4), 112.28 (C-5), 135.62 (C-6), 151.74 (C-2), 165.26 (C-4). UV
(H2O, pH 7), 	max 234 nm (ε 8,600), 270 nm (ε 2,160). HPLC retention time 

8.93 min (purity, 99%). Analysis (C9H11N3O4) was as follows. Calculated: C,
48.00; H, 4.92; N, 18.66. Found: C, 48.21; H, 4.85; N, 18.49.
1-(2-Deoxy--L-ribofuranosyl)-5-methylcytosine (-L-MetCdR) was character-
ized as a hydrochloride (white crystals from methanol with a few drops of HCl)
with a melting point of 151 to 153°C (decomposition). UV (H2O, pH 7) 	max 271
nm (ε 10,560), 	min 247 nm (ε 1,930); UV (H2O, pH 1) 	max 281 nm (ε 12,300),
	min 249 nm (ε 5,170). HPLC retention time 
 8.44 min (purity, 97%). Analysis
(C10H15N3O4, HCl) was as follows. Calculated: C, 43.25; H, 5.81; N, 15.13.
Found: C, 43.37; H, 5.68; N, 15.02. 1H NMR (DMSO-d6)  7.61 (1H, s, H-6), 7.26
(1H, br s, NH2), 6.77 (1H, broad singlet, NH2), 6.17 to 6.15 (1H, d, H-1), 5.21
(1H, s, OH-3), 5.07 (1H, s, OH-5), 4.20 (1H, d, H-3), 3.74 (1H, d, H-3), 3.57
to 3.42 (2H, m, H-5, H-5), 2.07 to 2.04 (1H, m, H-2), 1.97 to 1.92 (1H, m, H-2),
1.85 (3H, s, CH3). 13C NMR (DMSO-d6)  13.3 (CH3), 40.2 (C-2), 61.4 (C-5),
70.4 (C-3), 84.6 (C-1), 87.1 (C-4), 101.27 (C-5), 138.30 (C-6), 155.20 (C-2),
165.31 (C-4).
-L-dT was synthesized as described elsewhere (37). 3TC and -L-ddC were
synthesized according to published procedures (2, 17). FTC was kindly provided
by R. F. Schinazi, Emory University, Atlanta, GA.
Nucleoside 5-triphosphates of -L-deoxycytidine nucleosides were synthe-
sized via the monophosphates (39) as described previously for the corresponding
-D-counterparts (10) and were separated, purified, and characterized by matrix-
assisted laser desorption ionization–time-of-flight (MALDI-TOF) mass spec-
trometry as described elsewhere (37).
Unlabeled deoxynucleoside triphosphates were purchased from Roche Diag-
nostics, Mannheim,Germany, and [3H]dCTP (52 Ci/mmol) was purchased from
Amersham Biosciences, GmbH, Freiburg, Germany.
Estimations of anti-HBV activities of novel -L-nucleoside analogues in
HepG2.2.15 cells. The antiviral activities of the new compounds were estimated
in HepG2.2.15 cells, a human hepatoblastoma cell line with a replication-com-
petent HBV genome that produces infectious progeny viruses (31).
The cells were cultured under standardized conditions in Dulbecco’s modified
Eagle medium supplemented with 10% fetal bovine serum as described previ-
ously (15). Initially, about 105 cells were plated in 1 ml medium in each well of
a 12-well plate. Antiviral drugs were added at various concentrations with daily
medium changes. Cell culture supernatants and cells were harvested at treatment
day 3, 6, or 9 as indicated, and cell culture supernatants were subjected to PCR
analysis of HBV DNA (29).
For this purpose, the cell culture medium was cleared of cell debris, digested
with proteinase K, and used for PCR without further manipulation, employing
subgenomic forward primer F1 (5-CTC CAG TTC AGG AAC AGT AAA
CCC-3) and the corresponding reverse primer R1 (5-TTG TGA GCT CAG
AAA GGC CTT GTA AGT TGG CG-3). The following conditions were used:
10 cycles of 94°C for 40 s, 60°C for 90 s, and 70°C for 2 min; 30 cycles of 94°C for
40 s, 60°C for 90 s, and 70°C for 3.5 min; and 1 cycle of 70°C for 10 min. Serial
dilutions of a cloned HBV genome served for calibration of the PCR assay.
Intracellular HBV DNA was investigated after Southern blotting (29). The
intracellular viral DNA was purified from the cells after lysis in a buffer contain-
ing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 0.45% Tween, and 0.45% NP-40.
Proteins were digested with proteinase K, and viral DNA was extracted with
phenol-chloroform. Ethanol-precipitated DNA was dissolved in water and
loaded on an agarose gel for Southern blotting.
PCR products were separated on 1% agarose gels, stained with ethidium
bromide, and quantified by a Fluor-S MultiImager (Bio-Rad). For calibration of
the PCR, serial dilutions of plasmid pTHBV with known genome equivalents
(GE) were included in each PCR run. This standard showed a detection limit
of5 103 GE and linearity of the PCR between 5 103 and 5 105 GE. From
dose-response curves, the nucleoside analogue concentrations required for 50%
reduction of HBV DNA levels in the medium (50% effective concentrations
[EC50]) were estimated.
To investigate the duration of the antiviral effects of certain nucleoside ana-
logues, we performed washout experiments. Cells were treated with the indicated
drugs at a concentration corresponding to 5 times the EC50 for 6 days. Subse-
quently, the drugs were removed, and cells were further incubated for 3 and 6
days. Cells and culture supernatants were harvested, and the amount of HBV
DNA was determined.
Estimation of cytotoxicity in HepG2 and HL-60 cells. Human myeloid leuke-
mia (HL-60) and HepG2 cells were seeded at a density of 50,000 per well and
incubated in RPMI medium or Dulbecco’s modified Eagle medium, respectively,
for 3 days with varying concentrations of the compounds under humidified 5%
CO2–air at 37°C. Cell growth was monitored as described previously (33) by a
colorimetric reaction based on the capacity of cells to reduce 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan. Cytotoxicity
levels were expressed as concentrations that inhibited cell growth by 50% (CC50).
Endogenous HBV DNA polymerase assay. To determine endogenous HBV
DNA polymerase activity, about 125 ml of serum from patients with untreated
HBV infections with a titer of 107 HBV GE/ml (kindly provided by F. van
Bo¨mmel, Charite´, Berlin, Germany) was centrifuged at 3,000 rpm. Virus particles
in the cleared serum were sedimented using a Beckman SW28 rotor (25,000 rpm
for 60 min). The virus pellet was suspended in 7 ml of TKM buffer (50 mM
Tris-HCl, pH 7.5, 50 mM KCl, 5 mM MgCl2), layered over a step gradient of 10
ml each of 0.3 M, 0.6 M, and 0.9 M sucrose in TKM buffer, and centrifuged at
25,000 rpm for 20 h.
The purified virus pellet was suspended in 250 l TKM buffer, sonified, divided
into aliquots, and frozen at 80°C (4).
The HBV DNA polymerase assay mixture contained in 30 l about 2  108 to
4  108 virus particles (quantified by a VERSANT HBV DNA 3.0 assay with a
System 340 bDNA analyzer; Bayer, Wuppertal, Germany), and the assay was
performed in 42 mM Tris-HCl (pH 7.5), 34 mM MgCl2, 340 mM KCl, 22 mM
-mercaptoethanol, 0.4% Igepal, 70 M (each) dTTP, dATP, and dGTP, 1 Ci
[3H]dCTP (corresponding to 0.64 M dCTP), and varying concentrations of the
triphosphates of some of the novel -L-deoxycytidine derivatives and of two
reference nucleosides (20). After a 1-h incubation at 37°C, during which time the
incorporation of [3H]dCMP into HBV DNA had a linear course (27), 20-l
samples were processed for tritium measurement as described previously (22).
Using the concentration-dependent inhibition curves of HBV DNA synthesis,
the IC50 of the -L-nucleoside triphosphate inhibitors were determined.
RESULTS
Comparative effects of novel -L-deoxycytidine analogues on
HBV replication in vitro. The HBV producer cell line
HepG2.2.15 was used to evaluate the concentration-dependent
antiviral activities of the novel N4-hydroxy- and 5-methyl--L-
deoxycytidine derivatives in comparison to those of well known
inhibitors of HBV replication such as 3TC, FTC, -L-ddC, and
-L-dT. The structures of the most effective compounds, -L-
Hyd4C and -L-MetCdR, are given in Fig. 1. Antiviral effects
FIG. 1. Structures of the most effective compounds of the synthe-
sized N4-hydroxy- and 5-methyl--L-deoxycytidine analogues: -L-
Hyd4C and -L-MetCdR.
2524 MATTHES ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 O
ctober 22, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
were measured by analysis of levels of extracellular HBV DNA
from released virions, which decreased in a dose-dependent
manner for all compounds tested. The experimental data pre-
sented in Fig. 2 demonstrate that -L-Hyd4C was a more ef-
fective inhibitor than 3TC. In order to study the effects of the
analogues on the amount of intracellular HBV DNA, Southern
blot analysis of the lysed cells was performed. As expected,
-L-Hyd4C proved to be the most effective inhibitor of viral
DNA synthesis in treated cells as well (data not shown).
The EC50 for all compounds synthesized and tested are
summarized in Table 1. The EC50 for 3TC, FTC, -L-ddC, and
-L-dT were slightly higher than those described previously (3).
-L-Hyd4C was by far the most potent compound in this in
vitro system, with an EC50 of 0.03 M. The EC90 was estimated
to be 0.6 M.
-L-2,3-Dideoxy-3-thia-N4-hydroxycytidine (Hy3TC), -L-
2,3-dideoxy-N4-hydroxycytidine (-L-HyddC), and -L-MetCdR
gave EC50 between 0.51 M and 0.9 M. A second group of
compounds with EC50 between 2.38 M and 13 M includes
-L-N4-hydroxy-2-deoxycytidine (-L-HyCdR), -L-5-fluoro-N4-
hydroxy-2-deoxycytidine (-L-HyFCdR), -L-2,3-dideoxy-3-
thia-5-fluoro-N4-hydroxycytidine (HyFTC), -L-5-methyl-N4-hy-
droxy-2-deoxycytidine (-L-HyMetCdR), and -L-3-azido-2,
3-dideoxy-5-methylcytidine (-L-N3MetCdR). A third group of
nucleoside analogues including -L-2,3-dideoxy-3-fluoro-N4-
hydroxycytidine (-L-FHyCdR), -L-3-azido-2,3-dideoxy-N4-
hydroxycytidine (-L-N3HyCdR), -L-5-methylcytosine arabino-
side (-L-araMetC), -L-2,3-dideoxy-3-fluoro-5-methylcytidine
(-L-FMetCdR), -L-2,3-dideoxy-5-methylcytidine (-L-ddMetC),
and -L-2,3-didehydro-2,3-dideoxy-5-methylcytidine (-
L-d4MetC) were inactive (EC50, 25 M to 50 M).
Cellular toxicity of the -L-nucleosides. The compounds
were tested in vitro for their cytotoxicity. Table 1 shows that
they exhibited no significant antiproliferative activity against
HepG2 and HL-60 cells. The most active anti-HBV com-
pounds (-L-Hyd4C, Hy3TC, -L-HyddC, and -L-MetCdR)
have no effect on proliferation. Remarkably, for -L-Hyd4C,
CC50 of 2,500 M for HepG2 cells and 3,500 M for HL-60
cells were found.
Time dependence and recovery of the antiviral effects of the
new analogues. For the compounds -L-Hyd4C and Hy3TC,
we investigated the time dependency of the antiviral effect in
cell culture and measured the extracellular progeny virus DNA
in the culture medium of treated HepG2.2.15 cells in compar-
ison with those for 3TC. As judged from the HBV DNA-
specific PCR, the amount of HBV DNA in the supernatant of
treated cells decreased over time (Fig. 3). The antiviral activ-
ities of the compounds were evident at day 6 and continued at
day 9.
To test how long the antiviral activities of the compounds
lasted upon removal of the drugs, we performed a washout
assay. Cells were treated with 3TC, Hy3TC, or -L-Hyd4C at
concentrations 5 times the evaluated EC50 for 6 days. Then the
drugs were removed, and cells were further cultivated for 3 and
6 days. The amounts of extracellular and intracellular HBV
DNA were investigated for each time point by PCR and South-
ern blotting, respectively. As judged from both assays, time-
dependent increases in intracellular and extracellular viral
DNA levels were observed in 3TC- and Hy3TC-treated cells
after removal of the drugs (Fig. 4A to C). The recovery was
strongest at day 6 compared to day 3. This shows that viral
replication recovers from the drug treatment as expected, and
the data are consistent with published data (24).
In contrast to those for 3TC and Hy3TC, recovery after
FIG. 2. Dose-dependent inhibition of HBV DNA release from HepG2.2.15 cells 6 days after incubation with 0.1, 0.3, and 0.5 M 3TC, 0.1, 0.3,
and 0.5 M Hy3TC, and 0.05, 0.1, and 0.3 M -L-Hyd4C. HBV DNA was detected in the medium by PCR. Serial dilutions of a cloned HBV
genome (GE) served for calibration. For convenient quantification, dilutions of the PCR product from the untreated control corresponding to
100%, 50%, and 20% of the signal were used. “5 ” means that 5  10y GE (5) were used for PCR.
TABLE 1. Evaluation of novel -L-deoxycytidine derivatives
Compound
Anti-HBV activity in
HepG2.2.15 cells
(EC50)a
Inhibition of growth
(CC50)a of:
HepG2 cells HL-60 cells
Known inhibitors
3TC 0.1  0.025 1,200  265 1,400  310
FTC 0.1  0.028 765  145 845  174
-L-ddC 0.2  0.046 85  18.3 94  19.5
-L-dT 0.3  0.082 2,100  438 1,760  385
-L-N4-HyCdR
derivatives
-L-Hyd4C 0.03  0.009 2,500  572 3,500  794
Hy3TC 0.51  0.13 1,320  254 1,450  305
-L-HyddC 0.55  0.15 2,250  487 1,600  362
-L-HyCdR 2.38  0.56 545  144 460  98
-L-HyFCdR 4.50  1.3 920  231 1,370  289
HyFTC 5.0  1.3 855  196 770  163
-L-HyMetCdR 5.04  1.7 490  123 600  184
-L-FHyCdR 25  7.1 820  168 4,400  910
-L-N3HyCdR 50  14.6 1,160  241 2,000  431
-L-5-MetCdR
derivatives
-L-MetCdR 0.9  0.24 2,000 2,000
-L-N3MetCdR 13  3.9 1,750  197 1,900  410
-L-araMetC 50  15.0 2,000 2,000
-L-FMetCdR 50 1,800  350 1,650  396
-L-ddMetC 50 1,550  348 950  211
-L-d4MetC 50 1,400  343 600  167
a Results, in micromolar concentrations, are means  standard deviations for
at least three independent experiments.
VOL. 51, 2007 -L-N4-HYDROXY- AND 5-METHYL-DEOXYCYTIDINES FOR HBV 2525
 o
n
 O
ctober 22, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
-L-Hyd4C treatment was slower and was incomplete even 6
days after removal. This indicates that the antiviral activity of
this drug is more pronounced and is sustained over a longer
time than those of 3TC and Hy3TC. The delayed resumption
of HBV replication was not caused by a decreased number of
cells, because the antiproliferative activity of -L-Hyd4C is
lower than that of 3TC or Hy3TC (Table 1).
Inhibition of HBV DNA polymerase. To determine the di-
rect effects of some of the novel -L-nucleosides at the pre-
sumed viral target, we synthesized their triphosphates and ex-
amined them as inhibitors of HBV DNA polymerase. From
concentration-dependent inhibition curves, as shown for -L-
Hyd4C triphosphate and -L-MetCdR triphosphate (Fig. 5),
we estimated the IC50 given in Table 2. Table 2 demonstrates
that -L-Hyd4C triphosphate inhibited the presumed viral tar-
get more effectively than did 3TC triphosphate and -L-dTTP
(IC50, 0.21 M versus 0.30 and 0.46 M, respectively). Also,
the triphosphates of -L-N3MetCdR, -L-MetCdR, and -L-
HyddC were found to be strong inhibitors of HBV DNA
polymerase activity (IC50, 0.85 to 0.99 M), whereas the
triphosphates of -L-HyMetCdR, -L-HyCdR, -L-d4MetC,
-L-ddMetC, and -L-araMetC were less effective (IC50, 4.0
to 10.8 M).
DISCUSSION
In view of the experience that some nucleosides with the
unnatural -L configuration were more powerful and selective
antiviral agents than their corresponding -D isomers, we syn-
thesized and evaluated the corresponding opposite optical iso-
mers of some of the -D-MetCdR derivatives that we studied
several years ago. These investigations have shown that the
triphosphates of some of the -D-MetCdR derivatives are ex-
tremely powerful inhibitors of HBV DNA polymerase in vitro
(e.g., -D-3-FMetdCTP [IC50, 0.03 M]) (20), though they
proved to be less active under cell culture and in vivo condi-
tions (19, 21).
Now we found for the corresponding -L analogues that
-L-FMetCdR, -L-ddMetC, -L-d4MetC, and -L-araMetC as
well as their triphosphates were unable to inhibit either HBV
replication in HepG2.2.15 cells or cell-free HBV DNA poly-
merase activity (EC50, 50 M; IC50, 1.9 M to 10.8 M).
In contrast, -L-N3MetdCTP efficiently inhibited HBV DNA
polymerase activity (IC50, 0.85 M) but was nearly inactive as
the nucleoside in HepG2.2.15 cells (EC50, 13 M). Addition-
ally, we synthesized -L-MetCdR, which gained interest after
the discovery of -L-CdR as an efficient anti-HBV agent (EC50,
0.24 M) (3).
We show here that -L-MetCdR is a potent anti-HBV
agent in cell culture (EC50, 0.9 M) and that its triphos-
phate is an efficient inhibitor of HBV DNA polymerase
activity (IC50, 0.9 M).
It remains to be seen whether the monophosphate -L-
MetdCMP could be deaminated to -L-dTMP inside cells, a
reaction that might produce two anti-HBV active compounds:
-L-MetdCTP and -L-dTTP. At least for -L-dCMP, deami-
nation in HepG2 cells has been described (8).
A further modification we considered promising is the re-
placement of the 4-NH2 group by a 4-NHOH group in certain
-L-deoxycytidine analogues.
The corresponding -D enantiomer of deoxycytidine, -D-
N4-hydroxydeoxycytidine, was synthesized and investigated 40
years ago. It was found that this compound could be phosphor-
ylated in L5178Y leukemic cells and that the monophosphate
inhibited thymidylate synthase (23).
The corresponding -D-ribo derivative, -D-N4-hydroxycyti-
dine, was shown to be a strong mutagen for bacterial cells, phages,
and Neurospora crassa (5, 13, 25). Later, -D-N4-hydroxycytidine
was demonstrated to be an efficient inhibitor of bovine viral
diarrhea virus as well as in the hepatitis C virus replicon
system and of severe acute respiratory syndrome-associated
coronavirus (1, 36). These studies initiated the synthesis of
further -D- and -L-N4-hydroxycytidine analogues with a
3-deoxy and a 2-fluoro modification, respectively (11, 33).
We describe here the synthesis of novel 4-NHOH-modified
-L-deoxynucleosides and their inhibitory effects on HBV rep-
lication.
Of these compounds, -L-Hyd4C emerged as the most ef-
fective (EC50, 0.03 M), followed by Hy3TC and -L-HyddC
(EC50, 0.51 M and 0.55 M, respectively). The corresponding
derivatives with the unmodified 4-NH2 group, -L-d4C, 3TC,
and -L-ddC, suppressed HBV replication more efficiently
(EC50, 0.01 M, 0.017 M, and 0.01 M, respectively) (16, 17),
indicating a decline in antiviral activity associated with the
4-NHOH modification.
Surprisingly, the cytotoxicity of these compounds seems to
be much more decreased than their anti-HBV activity. Thus,
-L-Hyd4C and -L-HyddC displayed extremely low antipro-
FIG. 3. Time-dependent inhibition of HBV DNA release from HepG2.2.15 cells by 3TC, Hy3TC, and -L-Hyd4C. The cells were treated with
the indicated drugs for 3, 6, and 9 days. 3TC was used at 0.3 M, Hy3TC at 0.5 M, and -L-Hyd4C at 0.1 M. HBV DNA of the supernatants
was analyzed by PCR. Serial dilutions of a cloned HBV genome served for calibration of the PCR assay (GE). For convenient quantification,
dilutions of the PCR product from the untreated control corresponding to 100%, 50%, and 20% of the signal were used. , no treatment.
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liferative activities, as demonstrated by the CC50 of 2,500 M
for -L-Hyd4C and 2,250 M for -L-HyddC in HepG2 cells.
In comparison, the corresponding derivatives -L-d4C and -L-
ddC with the unmodified 4-NH2 group have CC50 of 20 M
and 70 M in CEM cells (16, 17). As a consequence, the
selectivity index of both 4-NHOH-modified compounds in-
creased dramatically.
Comparative analysis of the potencies of the antiviral sub-
stances showed that time-dependent inhibition of DNA repli-
cation in the cells occurs after treatment with all drugs tested.
FIG. 4. Recovery from the antiviral effect after cessation of drug treatment. 3TC was used at 1.5 M, Hy3TC at 2.5 M, and -L-Hyd4C at 0.5
M. (A) Southern blot analysis of HBV DNA of HepG2.2.15 cells treated for 6 days and incubated for a further 3 or 6 days in drug-free medium.
Arrows indicate the open circular (oc) and single-stranded (ss) forms of HBV DNA. (B) Quantitative evaluation of HBV DNA of these cells by
phosphorimaging. Means and standard deviations from two independent experiments are shown. The persistence of antiviral activity of -L-Hyd4C
upon removal of the drug was statistically significant compared to that for an untreated culture (P  0.0266). (C) PCR analysis of viral DNA in
the supernatants of the same cells. Serial dilutions of a cloned HBV genome and dilutions of PCR products of untreated cells served for the
calibration and quantification of the PCR signals. d, day; , no treatment.
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Prolongation of the treatment up to 9 days would reduce prog-
eny virus formation in a manner even more pronounced than
that observed after 6 days. The washout experiments suggest
that the antiviral effect of -L-Hyd4C seems to persist to a
certain degree even after removal of the drug. The recovery of
the level of HBV DNA seems to be delayed more effectively by
-L-Hyd4C than by 3TC, as shown for cells incubated 6 days in
drug-free medium.
It could be argued that the 4-NHOH group of the -L-
deoxycytidine derivatives might be reduced inside the cells to
the corresponding NH2 group, which was described as a pri-
mary catabolic step for the ribonucleoside -D-N4–hydroxycy-
tidine in Salmonella enterica serovar Typhimurium and liver
cells (9, 26). Such a reaction of our -L-N4-hydroxydeoxycyti-
dine analogues should produce drugs with much higher cyto-
toxicity. The extremely low cytotoxicity observed in our study
allows us to assume that this kind of modification is unlikely.
This view is supported further by the fact that Hy3TC is
inactive against HIV replication (E. Matthes et al., unpub-
lished data). If the NHOH group of Hy3TC were reduced to
the NH2 group, the resulting 3TC should display the well-
known highly efficient inhibition of HIV replication (EC50,
0.002 M) (30).
Furthermore, our results obtained with the presumed target,
HBV DNA polymerase, demonstrate that the 4-NHOH group
itself is responsible for the strong inhibition by triphosphates of
-L-Hyd4C and -L-HyddC (IC50, 0.21 M and 0.99 M).
Although the cellular metabolism of both groups of -L-
deoxycytidine derivatives presented here remains to be inves-
tigated, the results obtained with -L-Hyd4C and some other
derivatives indicate a unique and high selectivity index, which
FIG. 5. Inhibition of HBV DNA polymerase activity by -L-Hyd4C triphosphate (F) and -L-MetCdR triphosphate (E). Means and standard
deviations from three independent experiments are given.
TABLE 2. Inhibition of HBV DNA polymerase by triphosphates of
novel -L-deoxycytidine analogues in comparison to 3TC
triphosphate and -L-dTTP
Compound IC50 (M)
a for
the triphosphate
Known inhibitors
3TC (lamivudine)..............................................................0.30  0.05
-L-dT.................................................................................0.46  0.08b
-L-N4-HyCdR derivatives
-L-Hyd4C..........................................................................0.21  0.04
-L-HyddC .........................................................................0.99  0.16
-L-HyMetCdR ................................................................. 4.0  0.63
-L-HyCdR ........................................................................ 6.0  0.84
-L-5-MetCdR derivatives
-L-N3MetCdR..................................................................0.85  0.17
-L-MetCdR ......................................................................0.90  0.16
-L-FMetCdR.................................................................... 1.9  0.42b
-L-d4MetC........................................................................ 6.2  0.99
-L-ddMetC ....................................................................... 6.5  1.1
-L-araMetC ......................................................................10.8  1.9
a Results are means  standard deviations from at least three independent
experiments.
b Result from reference 37.
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makes them candidates for further investigations as potential
anti-HBV agents.
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